Date lodged: 29 May 2018
To ask the Scottish Government, in light of the findings of the report, Review of Access to New Medicines, what progress has been made in ensuring access to treatments for (a) phenylketonuria and (b) other rare diseases.
Answered by: Shona Robison 6 June 2018
I wrote to the Health and Sport Committee on 17 May to provide a further update on the Scottish Government’s progress in delivering the recommendations from the Review of Access to New Medicines.
I can confirm that the pharmaceutical company, BioMarin, has made a submission to the Scottish Medicines Consortium (SMC) for sapropterin (Kuvan®) for the treatment of phenylketonuria. The SMC will publish their advice in August.
Decisions made by the SMC are independent of Ministers and the Parliament.